Literature DB >> 14551288

Evidence for a selective role of the delta-opioid agonist [8R-(4bS*,8aalpha,8abeta, 12bbeta)]7,10-Dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses.

Paola Petrillo1, Ornella Angelici, Sharon Bingham, Giovanna Ficalora, Martine Garnier, Paola F Zaratin, Giuseppe Petrone, Ottorino Pozzi, Massimo Sbacchi, Tania O Stean, Neil Upton, Guillio M Dondio, Mark A Scheideler.   

Abstract

The specific involvement of the delta-opioid receptor in the control of nociception was explored by investigating the pharmacological activity in vivo of a selective, orally active, and centrally penetrant delta-opioid agonist. [8R-(4bS*,8aalpha,8abeta,12bbeta)]7,10-dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) is a new pyrrolomorphinan with high affinity (Ki = 4.81 +/- 0.39 nM) for the delta-opioid receptor, full agonist activity, and binding selectivity versus the mu- and kappa-opioid receptors of 189-fold and 52-fold, respectively. Perorally administered SB-236863 was inactive in the rat tail-flick and hot-plate tests of acute pain response, but potently reversed thermal hyperalgesia in rats resulting from a carrageenan-induced inflammatory response. This activity could be blocked by the delta-opioid antagonist naltrindole (3 mg/kg s.c.), but selective mu- and kappa-opioid antagonists were ineffective. Naltrindole (1 microg i.c.v.) also blocked the activity of 10 mg/kg (p.o.) SB-235863, showing that the compound activates delta-opioid receptor sites in the central nervous system. SB-235863 was additionally effective at reversing chronic hyperalgesia in the Seltzer rat model of partial sciatic nerve ligation after peroral administration. These data show that the delta-opioid receptor plays a selective role in regulating evoked and lasting changes in nociceptive pain signaling. Classical side effects of mu- and kappa-opioid receptor activation (slowing of gastrointestinal transit and motor incoordination, respectively) were not observed after administration of 70 mg/kg (p.o.) SB-235863, nor was evoked seizure activity affected. These results suggest a selective and limited role of delta-opioid receptors in the modulation of nociception.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551288     DOI: 10.1124/jpet.103.055590

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  36 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.

Authors:  Claire Gavériaux-Ruff; Brigitte Lina Kieffer
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

3.  Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the δ-Opioid Receptor.

Authors:  Arnaud Proteau-Gagné; Véronique Bournival; Kristina Rochon; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2010-09-17       Impact factor: 4.418

4.  Preparation and evaluation at the delta opioid receptor of a series of linear leu-enkephalin analogues obtained by systematic replacement of the amides.

Authors:  Kristina Rochon; Arnaud Proteau-Gagné; Philippe Bourassa; Jean-François Nadon; Jérome Côté; Véronique Bournival; Fernand Gobeil; Brigitte Guérin; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2013-05-20       Impact factor: 4.418

Review 5.  The role of δ-opioid receptors in learning and memory underlying the development of addiction.

Authors:  Paul Klenowski; Michael Morgan; Selena E Bartlett
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

6.  Targeting Cannabinoid 1 and Delta Opioid Receptor Heteromers Alleviates Chemotherapy-Induced Neuropathic Pain.

Authors:  Salvador Sierra; Achla Gupta; Ivone Gomes; Mary Fowkes; Akila Ram; Erin N Bobeck; Lakshmi A Devi
Journal:  ACS Pharmacol Transl Sci       Date:  2019-06-05

Review 7.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 8.  Alleviating pain with delta opioid receptor agonists: evidence from experimental models.

Authors:  Sophie Berthiaume; Khaled Abdallah; Véronique Blais; Louis Gendron
Journal:  J Neural Transm (Vienna)       Date:  2020-03-18       Impact factor: 3.575

9.  Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia.

Authors:  L Gendron; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-10-05       Impact factor: 3.590

10.  δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice.

Authors:  Amynah A Pradhan; Monique L Smith; Jekaterina Zyuzin; Andrew Charles
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.